STOCK TITAN

Nutriband Inc - NTRB STOCK NEWS

Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.

Overview

Nutriband Inc is a Florida-based pharmaceutical company specializing in the development of transdermal drug delivery systems that incorporate advanced abuse-deterrent technologies. Its core business revolves around transdermal pharmaceutical products engineered to mitigate the risks of drug abuse, misuse, diversion, and accidental exposure, with a special emphasis on addressing the global opioid crisis. Utilizing proprietary technology that integrates aversive agents into transdermal patches, Nutriband is dedicated to improving patient safety while ensuring essential medications remain accessible for those in need.

Advanced Abuse-Deterrent Technology

The company’s flagship innovation, AVERSA technology, is designed to deter the oral abuse of potent drugs by utilizing taste aversion methods. This technology can be incorporated into various transdermal patches, a critical step toward preventing accidental exposures—particularly in vulnerable populations such as young children. The patented approach provides an additional safeguard by making the potential for abuse less appealing, thereby enhancing the overall safety profile of drugs with abuse potential.

Business Model and Operations

Nutriband Inc generates revenue primarily through the sale of consumer transdermal and coated products, as well as through contract manufacturing services provided by its wholly owned subsidiary, Pocono Pharma. The company leverages its strategic partnerships with top industry players to extend its market reach, including engagements with major retailers and established pharmaceutical manufacturing organizations. This diversified revenue approach not only supports the current portfolio but also positions Nutriband as a flexible partner in both the healthcare and contract manufacturing sectors.

Strategic Partnerships and Intellectual Property

A cornerstone of Nutriband’s success is its robust global intellectual property portfolio, which spans across more than 40 countries including the United States, Europe, Japan, and Australia. Such extensive protection underpins its innovative AVERSA technology and provides a competitive edge in the increasingly critical field of abuse-deterrent transdermal systems. Strategic alliances with industry experts such as Kindeva Drug Delivery further reinforce its position by ensuring that large-scale manufacturing processes align with FDA guidelines and international industry standards.

Market Position and Industry Significance

Operating at the nexus of pharmaceutical innovation and patient safety, Nutriband Inc is positioned distinctively in the competitive landscape of transdermal drug delivery systems. Its strategic focus on developing abuse-deterrent products addresses a significant unmet need in the market, particularly in the context of managing opioid-related risks without compromising therapeutic access. Through its commitment to evolving industry standards and enhancing product safety, Nutriband has established itself as a forward-thinking entity within a critical market segment.

Product Portfolio and Future Applications

While its lead product, an abuse-deterrent fentanyl patch, remains at the forefront of its development efforts, Nutriband is actively expanding its portfolio to include additional transdermal therapies. By integrating its core AVERSA technology across multiple product lines, the company aims to address a wide spectrum of medications with abuse potential, including opioids and stimulants. This strategy not only diversifies its technology applications but also solidifies its reputation as an innovator in transdermal pharmaceutical solutions.

Commitment to Safety and Regulatory Compliance

At the heart of Nutriband’s mission is a dedication to enhancing patient safety through rigorous research, development, and close adherence to regulatory standards. The company emphasizes clear, methodical approaches that streamline market entry while upholding the highest safety measures. This balance of innovation and compliance is critical in a market where the prevention of misuse and accidental exposure is of paramount concern.

Overall, Nutriband Inc exemplifies a strategic blend of innovative product development, methodical market expansion, and a steadfast commitment to patient safety. Its robust technology platform, significant IP portfolio, and established industry partnerships underscore its role as a key contributor to the evolution of abuse-deterrent pharmaceutical products.

Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that its manufacturing subsidiary, Active Intelligence, has successfully received cGMP certification after a thorough audit. This certification is vital for expanding their contract manufacturing services on a national and international scale. CEO Gareth Sheridan highlighted that this achievement will enable the company to enhance its product offerings and explore new market opportunities, which are crucial for the company’s growth strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
none
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that its CEO Gareth Sheridan and President Serguei Melnik, accompanied by board members and senior management, will ring the NASDAQ Opening Bell on December 3, 2021, at 9:30 a.m. EST. Sheridan expressed gratitude for the teamwork and support that enabled the company’s journey so far. Nutriband focuses on developing transdermal pharmaceutical products, including its lead product, an abuse deterrent fentanyl patch utilizing AVERSA™ technology. A live stream of the ceremony will be available online.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.43%
Tags
none
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has launched the development of its lead product, AVERSA™ Fentanyl, aiming to create the world’s first abuse-deterrent fentanyl transdermal system. This initiative follows the company's uplisting to NASDAQ and new financing. The focus will include developing a commercial strategy, market assessment, and selecting a manufacturer to expedite market entry. CEO Gareth Sheridan emphasized the importance of improving safety while ensuring accessibility for patients. Nutriband specializes in transdermal pharmaceutical products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
none
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that an interview with CEO Gareth Sheridan will air on The RedChip Money Report on Bloomberg TV on November 13 at 7 p.m. ET. The program reaches approximately 73 million homes in the U.S. RedChip has 30 years of experience in small-cap investing commentary and interviews with public company executives.

Nutriband is focused on developing transdermal pharmaceutical products, including its lead product, an abuse deterrent fentanyl patch utilizing AVERSA® technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.96%
Tags
none
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced the receipt of $2,062,500 from the exercise of 275,000 warrants at $7.50 each, linked to its earlier public offering on October 1, 2021. This adds to the $6,600,000 garnered from the sale of 1,056,000 shares, bringing the total gross proceeds to approximately $8,662,500 as of October 21, 2021. Nutriband focuses on developing transdermal pharmaceutical products, particularly an abuse deterrent fentanyl patch utilizing its AVERSA technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.81%
Tags
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) has entered an exclusive manufacturing agreement with Diomics for its Diocheck™ technology, aimed at monitoring COVID-19 antibody levels. This transdermal patch provides results within 24 to 36 hours and remains effective for up to 14 days. The device is intended for assessing the effectiveness of COVID-19 vaccines over time, helping identify when boosters may be needed. The partnership showcases Nutriband's capabilities in innovative patch technologies, bolstering its position in the pharmaceutical market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.08%
Tags
covid-19
Rhea-AI Summary

WallachBeth Capital has successfully completed an underwritten public offering for Nutriband Inc. (NASDAQ: NTRB), raising $6.6 million by issuing 1,056,000 units at $6.25 per unit. Each unit contains one share of common stock and one warrant, with the warrants priced at $7.50 for five years. A 45-day option to purchase additional shares and warrants has been granted to underwriters. The offering commenced trading on October 1, 2021, on the Nasdaq Capital Market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ: NTRB, NTRBW) announced an underwritten public offering of 1,056,000 units priced at $6.25 per unit, generating gross proceeds of $6.6 million. Each unit consists of one share of common stock and one warrant. The warrants are exercisable at $7.50 and expire in five years. The offering includes a 45-day option for underwriters to purchase additional shares and warrants. This uplisting to the Nasdaq Capital Market aims to enhance visibility and support the company's strategic growth initiatives in developing transdermal pharmaceutical products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that it received a Notice of Allowance from the USPTO for patent application 16/707,547, focusing on its AVERSA® technology. This technology targets the prevention of opioid abuse, particularly for fentanyl patches. The announcement follows the company's initial NASDAQ listing and a $6.6 million underwritten offering on October 1, 2021. The proceeds will primarily fund the clinical development of AVERSA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Nutriband Inc. (NASDAQ: NTRB, NTRBW) announced its common stock and warrants began trading on the Nasdaq Capital Market on October 1, 2021. The company also priced an underwritten public offering of 1,056,000 units at $6.25 per unit, aiming for total gross proceeds of $6.6 million. Each unit comprises one share of common stock and one warrant, entitling the holder to purchase additional stock at an exercise price of $7.50. A 45-day option allows underwriters to purchase up to 158,400 additional shares to cover over-allotments. CEO Gareth Sheridan noted that this uplisting is a significant milestone for corporate visibility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Nutriband (NTRB)?

The current stock price of Nutriband (NTRB) is $5.77 as of April 2, 2025.

What is the market cap of Nutriband (NTRB)?

The market cap of Nutriband (NTRB) is approximately 63.4M.

What is Nutriband Inc's core business?

Nutriband Inc focuses on the development of transdermal pharmaceutical products using innovative abuse-deterrent technology. The company is dedicated to enhancing patient safety by preventing the misuse and accidental exposure of drugs with abuse potential.

How does the AVERSA technology work?

AVERSA technology incorporates aversive agents into transdermal patches to deter drug abuse by triggering an immediate taste aversion. This approach reduces the likelihood of misuse, diversion, or accidental ingestion of potent medications.

What are the key revenue streams for Nutriband Inc?

The company generates revenue primarily through the sale of consumer transdermal and coated products, as well as through its contract manufacturing services via its subsidiary, Pocono Pharma. These diversified streams support both product development and manufacturing partnerships.

How does Nutriband position itself within the pharmaceutical industry?

Nutriband occupies a strategic niche in the pharmaceutical sector by targeting the critical issue of drug abuse. Its advanced abuse-deterrent technology and robust intellectual property portfolio distinguish its products, particularly in addressing opioid-related safety concerns.

What strategic partnerships support Nutriband's operations?

Nutriband collaborates with respected industry partners like Kindeva Drug Delivery and Pocono Pharma. These partnerships enhance its manufacturing capabilities and ensure compliance with regulatory standards, broadening its market reach.

In which markets are Nutriband's products available?

While Nutriband is based in the United States, its operations and intellectual property extend globally, covering key markets in Europe, Japan, Australia, and more. The company’s strategic licensing and distribution agreements support international market penetration.

How is Nutriband addressing the opioid crisis?

Nutriband is developing abuse-deterrent transdermal solutions specifically designed to mitigate opioid misuse. By incorporating aversive agents into its patches, the company aims to prevent both intentional abuse and accidental exposure.

How does Nutriband protect its innovative technology?

The company maintains a comprehensive global intellectual property portfolio with patents issued in over 40 countries. This extensive protection secures its AVERSA technology and reinforces its competitive advantage in the transdermal pharmaceutical space.
Nutriband Inc

Nasdaq:NTRB

NTRB Rankings

NTRB Stock Data

63.42M
3.30M
70.29%
2.1%
2.53%
Biotechnology
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
ORLANDO